中国药房2025，Vol.36Issue(16)：2024-2029,6.DOI:10.6039/j.issn.1001-0408.2025.16.12
芦康沙妥珠单抗对比单药化疗用于转移性三阴性乳腺癌二线及后线治疗的成本-效果分析
Cost-effectiveness analysis of sacituzumab tirumotecan versus single-agent chemotherapy in second-line and later-line treatment for metastatic triple-negative breast cancer
摘要
Abstract
OBJECTIVE To evaluate the cost-effectiveness of sacituzumab tirumotecan(ST)versus chemotherapy treatment physician's choice(TPC)as second-line and later-line treatment for metastatic triple-negative breast cancer(mTNBC)from the perspective of China's healthcare system.METHODS A partitioned survival model was constructed based on the OptiTROP-Breast 01 trial,with a cycle length of 4 weeks and a time horizon of 10 years,applying a 5%discount rate.Quality adjusted life year(QALY)and costs were used as outcome measures,and the incremental cost-effectiveness ratio(ICER)of ST versus TPC for second-line and later-line treatment of mTNBC was calculated.Sensitivity analyses were conducted to validate the robustness of the base-case results.RESULTS At a willingness-to-pay threshold(WTP)of 3 times China's 2024 per capita gross domestic product(GDP)(287 247 yuan/QALY),patients receiving ST gained incremental utility(0.42 QALY)at a higher cost,yielding an ICER of 205 562.07 yuan/QALY,which was lower than WTP,indicating that ST was more cost-effective compared to TPC.One-way sensitivity analysis revealed that key factors influencing the ICER included the utility value of progression-free survival and the price of ST.Probabilistic sensitivity analysis and scenario analysis showed that the base-case results were robust.CONCLUSIONS From the perspective of China's healthcare system,at a WTP of 3 times China's per capita GDP,ST is more cost-effective than TPC as second-line and later-line treatment for mTNBC.关键词
芦康沙妥珠单抗/转移性三阴性乳腺癌/二线治疗/后线治疗/分区生存模型/成本-效果分析Key words
sacituzumab tirumotecan/metastatic triple-negative breast cancer/second-line treatment/later-line treatment/partitioned survival model/cost-effectiveness analysis分类
医药卫生引用本文复制引用
张冉冉,张羽曦,高胜男,冯冰,高宁,刘国强..芦康沙妥珠单抗对比单药化疗用于转移性三阴性乳腺癌二线及后线治疗的成本-效果分析[J].中国药房,2025,36(16):2024-2029,6.基金项目
河北省自然科学基金项目(No.H2021206407) （No.H2021206407）
